ALERT!
This site is not optimized for Internet Explorer 8 (or older).
Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.
Will TAVR Become the Predominant Method for Treating Severe Aortic Stenosis?
Sunday, April 3, 2016
Submitted by
Source
Source Name: New England Journal of Medicine
Neil Moat, one of the busiest British surgeons involved directly and consistently in TAVR, discusses PARTNER 2 and SURTAVI, paying particular attention to the health economics of low-risk TAVR and the implication of reduced profile devices.
Printer-friendly
